Related Experiment Video
Updated: Jun 29, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Definitive radiotherapy for prostate cancer.
William M Mendenhall1, Randal H Henderson, Nancy P Mendenhall
1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610-0385, USA. mendwm@shands.ufl.edu
American Journal of Clinical Oncology
|October 8, 2008
Summary
Predicting extraprostatic disease in prostate cancer is possible using clinical factors. Radiotherapy (RT) offers a high cure likelihood for localized or locally advanced prostate cancer, especially with dose escalation.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Background:
- Prostate cancer management depends on disease extent.
- Accurate staging is crucial for treatment selection.
Purpose of the Study:
- To outline the prognostic factors for extraprostatic disease.
- To review treatment strategies for localized and locally advanced prostate cancer.
- To discuss the role of radiotherapy (RT) and dose escalation.
Main Methods:
- Estimation of extraprostatic disease using clinical T-stage, PSA, Gleason score, and biopsy data.
- Review of treatment outcomes for prostatectomy versus RT.
- Analysis of RT techniques including external beam and brachytherapy.
- Evaluation of dose escalation and androgen deprivation therapy (ADT) impact.
Main Results:
- Clinical factors accurately predict extraprostatic disease.
- RT provides high cure rates for localized and intermediate-risk prostate cancer.
- Dose-escalated RT improves biochemical relapse-free survival.
- ADT may enhance disease control in high-risk cases.
Conclusions:
- Prognostic factors guide treatment decisions for prostate cancer.
- Radiotherapy is a primary curative option for various stages of prostate cancer.
- Optimizing RT dose and incorporating ADT are key for improved outcomes.
